Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous TAK-954 in Critically Ill Patients With Enteral Feeding Intolerance

Trial Profile

A Phase 2b, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous TAK-954 in Critically Ill Patients With Enteral Feeding Intolerance

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2018

At a glance

  • Drugs TD 8954 (Primary) ; Metoclopramide
  • Indications Gastrointestinal disorders
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 13 Dec 2018 Status changed from recruiting to discontinued.
    • 28 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 31 Jul 2018 Status changed to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top